AbbVie and Genmab's Epcoritamab Fails Primary Survival Endpoint in Phase 3 Trial

Key Facts

In a development highlighting the ongoing challenges in the biotech sector's pursuit of advanced oncology treatments, AbbVie and Genmab reported disappointing results from a major clinical study. The companies announced that the Phase 3 EPCORE DLBCL-1 trial, evaluating epcoritamab monotherapy for lymphoma, did not meet its primary endpoint of improving overall survival. According to reports, the study failed to demonstrate a statistically significant improvement when compared to standard chemoimmunotherapy.

The trial was intended to confirm the clinical benefit of the drug in the U.S. market, where it is already approved under accelerated pathways, but the latest data did not meet the required survival thresholds. This news comes at a critical time for AbbVie (ABBV) as investors closely monitor the company's ability to offset legacy drug revenue declines through its oncology pipeline. The trial failure exerts bearish pressure on the stock's near-term outlook despite its continued approval in other treatment lines.

Regarding stock performance, ABBV was priced at $256.1 (at close July 21, 2026), with a daily range between $252.6 and $257.06 per market data. Healthcare sector traders are now awaiting further updates from the companies regarding the publication of full results in medical journals, while the current economic calendar shows no immediate sector-specific catalysts in the coming days.